Drug Profile
Tumour infiltrating lymphocytes - National Institutes of Health/Bristol-Myers Squibb
Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Non-small cell lung cancer; Renal cancer